Connect
Has anyone developed MCAS since Covid?
I have had Covid twice - in 2022 and again in 2025. I took all the shots so when I got sick it wasn't serious, miserable but not serious. Ever since the first bout I haven't been the same. I had the infection in 7/22 and I started gaining weight because I was extremely fatigued and out of breath alot and my appetite kicked up. By January of 2023 I could not tolerate a long list of food that previously were not a problem. Example: oatmeal. the gas, bloating, fatigue and shortness of breath after eating oatmeal was off the charts. Then yeast, then quinoa, then chick peas.. it just goes on. In 2/23 I started getting severe pelvic and lower back pain that was relentless and connected to almost anything I ate. I tested positive for UTI and took 3 rounds of antibiotics because it kept "coming back" which killed my diarrhea but also the rest of my GI system. I've gained 15 pounds in 3 years, have crazy food sensitivities that seem to come from no where and I literally can't keep my eyes open after I eat. I sweat after a shower, and have the chills and cold hands when it's 80 degrees outside. Bloodshot eyes, smelly urine and gas from hell. I started taking claritin a few weeks ago- seems to help a teeny bit, but started Wegovy last week and felt like a normal human being again for the first time in 4 years. I'm trying to find a doctor who can help. I have seen 10 in 3 years and all tests come back "normal".
Like
Helpful
HugInterested in more discussions like this? Go to the Post-COVID Recovery & COVID-19 Support Group.
Connect
BTW @djg3012 , @diverdown1 , @covidstinks2023 all- look at this: I just found this online TODAY!!
The Core Science: Mast Cells Express GLP-1 ReceptorsMechanism of Action: Peer-reviewed immunological data shows that human mast cells express GLP-1 receptors on their cellular surfaces.Stabilization Effect: When a GLP-1 receptor agonist (such as semaglutide) binds to these receptors, it acts as a direct mast cell stabilizer. It down-regulates the release of pro-inflammatory mediators, pro-inflammatory cytokines (like IL-6 and TNF-α), and systemic histamine.2. The Landmark July 2025 Case Series (Afrin, Weinstock, Dempsey)Study Citation: Afrin LB, Weinstock LB, Dempsey T, et al. "Utility of glucagon-like-peptide-1-receptor agonists in mast cell activation syndrome." The American Journal of the Medical Sciences.The Cohort: The study evaluated 47 patients with treatment-resistant, refractory MCAS who had failed conventional histamine-blockade therapy.The Efficacy Rate: An astounding 89% of MCAS patients demonstrated meaningful clinical benefit across a wide range of multisystem symptoms, including gastrointestinal inflammation, neurological flares, and profound fatigue.Clinical Observation: Many patients reported rapid, dramatic improvements in food tolerances and a reduction in localized GI pain within weeks of initiating therapy.
@covidstinks2023 ...HUH?Yeah...this person has LONG COVID.Wow.WE ALL here have been infected with the killer from China.We wouldn't be on this forum if we didn't have this deal.This isn't the first time China has developed viruses that kill people.